Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 15;11(7):984.
doi: 10.3390/cancers11070984.

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

Ghaneya Al-Khadairi  1 , Julie Decock  2   3
Affiliations
Review

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

Ghaneya Al-Khadairi et al. Cancers (Basel). .

Abstract

PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.

Keywords: PRAME; adoptive T cell therapy; antibody; cancer testis antigen; cancer vaccine; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Immunotherapy approaches to target specific tumor-associated antigens such as PRAME.
See this image and copyright information in PMC

References

    1. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011;365:1273–1283. doi: 10.1056/NEJMoa0910383. - DOI - PMC - PubMed
    1. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed
    1. Lv Z.-C., Ning J.-Y., Chen H.-B. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis from 12 randomized controlled trials. Tumor Biol. 2014;35:11741–11750. doi: 10.1007/s13277-014-2227-z. - DOI - PubMed
    1. Zhang H., Chen J. Current status and future directions of cancer immunotherapy. J. Cancer. 2018;9:1773–1781. doi: 10.7150/jca.24577. - DOI - PMC - PubMed
    1. Hinrichs C.S., Rosenberg S.A. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 2014;257:56–71. doi: 10.1111/imr.12132. - DOI - PMC - PubMed

LinkOut - more resources